Longeveron (LGVN) Other Non-Current Assets (2021 - 2026)
Longeveron (LGVN) recorded quarterly Other Non-Current Assets of $18000.0 in Q1 2026, down 89.77% quarter-over-quarter from $176000.0 in Q4 2025, and down 91.04% on a YoY basis from $201000.0 in Q1 2025.
Longeveron (LGVN) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Longeveron's Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 91.04% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $18000.0 (down 91.04% YoY), while the FY2025 annual figure was $176000.0, down 12.87% from the prior year.
- Other Non-Current Assets was $18000.0 for Q1 2026 at Longeveron, down from $176000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $247000.0 in Q1 2023 to a low of $18000.0 in Q1 2026.
- Historically, Other Non-Current Assets has averaged $191142.9 across 5 years, with a median of $200500.0 in 2025.
- The sharpest annual moves came in 2022 and 2026: Other Non-Current Assets jumped 37.85% in 2022, then tumbled 91.04% in 2026.
- A 5-year view of Other Non-Current Assets shows it stood at $244000.0 in 2022, then fell by 20.9% to $193000.0 in 2023, then rose by 4.66% to $202000.0 in 2024, then fell by 12.87% to $176000.0 in 2025, then sank by 89.77% to $18000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $18000.0 (Q1 2026), $176000.0 (Q4 2025), and $178000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 176,000.00 |
| Sep 30, 2025 | 178,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 201,000.00 |
| Dec 31, 2024 | 202,000.00 |
| Sep 30, 2024 | 203,000.00 |
| Jun 30, 2024 | 204,000.00 |
| Mar 31, 2024 | 190,000.00 |
| Dec 31, 2023 | 193,000.00 |
| Sep 30, 2023 | 197,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Mar 31, 2023 | 247,000.00 |
| Dec 31, 2022 | 244,000.00 |
| Dec 31, 2021 | 177,000.00 |